Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients With Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-0560
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2007
Authors
Publisher
American Association for Cancer Research (AACR)